Touchlight’s circular DNA offerings introduces a suite of innovative architectures, mbDNA, sscDNA, hsscDNA, and dscDNA, designed to overcome the limitations of traditional gene editing tools. These constructs offer enhanced stability, reduced immunogenicity, and compatibility with a broad range of gene insertion technologies.

Click here to download the product brief 

Replacing plasmid DNA with enzymatically produced DNA in your AAV production eliminates many issues around complex or unstable sequences, purity, speed to manufacture, safety and scalability.

Many biotech and pharma companies focused on advanced therapies are taking advantage of enzymatic DNA to deliver rapid AAV production using less DNA.

Download the product brief to explore the data.